Mahamaya Lifesciences Ltd. IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 2,928,000 (47%) | — | ₹3,338 Cr |
| NII (HNI) | — | 882,000 (14%) | — | ₹1,005 Cr |
| Retail | — | 2,059,200 (33%) | — | ₹2,347 Cr |
| Market Maker | — | 309,600 (5%) | — | ₹35 Cr |
| Σ Total | — | 6,178,800 (100%) | — | ₹70,438 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 1,200 | ₹136,800 |
| Retail (Max) | 13 | 15,600 | ₹1,778,400 |
| S-HNI (Min) | 14 | 16,800 | ₹1,915,200 |
| B-HNI (Min) | 67 | 80,400 | ₹9,165,600 |
Financial Statements Amount in ₹ Crore
| Metric | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Revenue | 84 | 267 | 163 |
| EBITDA | 8 | 25 | 13 |
| Profit After Tax | 4 | 13 | 5 |
| Net Worth | 54 | 49 | 25 |
| Total Assets | 219 | 188 | 112 |
| Reserves & Surplus | 36 | 32 | 23 |
| Total Borrowing | 58 | 58 | 55 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- 1 Purchase of Equipment for existing Formulation plant – 3.75
- 2 Funding capital expenditure towards setting up of a new technical manufacturing plant – 29.42
- 3 Construction of Warehouse Building and Purchase of Machinery – 2.53
- 4 Funding working capital requirement of our Company – 18.00
- 5 General Corporate purposes –
Company Overview
Incorporated in 2002, Mahamaya Lifesciences Limited is engaged in manufacturing, registration and export of finest crop protection products and bioproducts for crop & soil health management and to help the farming community for more productivity.
The company specializes in manufacturing pesticide formulations and supplying bulk products to Indian agrochemical companies and multinational corporations (MNCs).
The company imports carefully researched molecules, registers them with the Central Insecticides Board, and markets them as technical and value-added formulations for domestic manufacturers and multinational corporations (MNCs).
The company has invested in global product registrations, with active markets in countries like the Dominican Republic, Egypt, Ethiopia, Jordan, UAE, and Turkey, offering high-quality products and data support for registrations.
Product Portfolio:
- Bulk Formulations Sales: Acetamiprid, SP Buprofezin, SC Emamectin benzoate, SG Imidacloprid, SC Paraquat Dichloride.
- Technical Sales: Acetamiprid Technical 99% Min, Atrazine Technical 95% Min, Imidacloprid Technical 95% Min, Emamectin Benzoate Technical 95% Min.
- Branded Sales (Major own branded products): MAYAMRIT GR, MAYAMRIT SL, MAYAGIBB, UCHIT EW 370
- Export Sales- Formulations: Wiper (Sulphur 80% WDG), Lancha (Pendimethalin 50% EC), Tolfen (Tolfenpyrad 15% EC), Typic (80% Sulphur WG).
Competitive Strengths:
- Experienced management team consisting of experts.
- Capability to introduce vital products for Indian Agriculture.
- Development of export opportunities of products.
- Ability to develop brands.
- Cordial relationships with suppliers of raw materials.
- Core values focused on achieving sustainability through innovative approaches.